Redsenol-1 Plus Gains Prestigious Recognition in National Cancer Institute's Drug Dictionary
TL;DR
Redsenol-1 Plus's unique rare ginsenosides give it an advantage over conventional ginseng supplements, making it a standout in the market.
Redsenol-1 Plus is defined in the NCI Drug Dictionary as an oral herbal supplement with sixteen rare ginsenosides derived from ginseng.
Redsenol-1 Plus's potential in oncology and supportive care showcases Canada Royal Enoch Phytomedicine's commitment to advancing cancer research.
Redsenol-1 Plus features highly bioactive and absorbable rare ginsenosides, setting it apart in the ginseng supplement industry.
Found this article helpful?
Share it with your network and spread the knowledge!
A groundbreaking ginsenoside supplement has secured a notable position in the scientific community after being officially recognized by the National Cancer Institute (NCI). Redsenol-1 Plus, developed by Canada Royal Enoch Phytomedicine, has been added to the NCI Drug Dictionary, becoming the first product in the global multi-component ginsenoside industry to receive this distinguished listing.
The NCI Drug Dictionary serves as a critical reference for technical definitions of cancer-related drugs and agents. Redsenol-1 Plus stands out for its unique composition, featuring sixteen rare ginsenosides at a 20% concentration, significantly higher than conventional ginseng extract supplements that typically contain only 4% total ginsenosides.
Unlike traditional ginseng supplements that primarily contain large-molecule, poorly absorbed ginsenosides, Redsenol-1 Plus offers a diverse profile of highly bioactive and absorbable compounds. The supplement includes rare ginsenoside monomers such as Rg3, Rh1, Rh2, and others, which represent a significant advancement in herbal supplement technology.
The inclusion in the NCI Drug Dictionary coincides with an ongoing clinical trial investigating the supplement's potential in managing cancer-related fatigue. The triple-blind, placebo-controlled study, conducted by KGK Science, Inc., aims to evaluate Redsenol-1 Plus's efficacy in addressing a common and debilitating symptom experienced by cancer patients during treatment.
Dr. Peihua Yu, founder and CEO of Canada Royal Enoch Phytomedicine, emphasized the significance of this recognition, noting that the standardized definition offers researchers a comprehensive understanding of the supplement's components. The company's proprietary extraction and processing technologies have enabled the large-scale production of these valuable compounds, positioning them as a global leader in ginsenoside innovation.
This recognition represents more than a mere technical achievement. It signals a potential breakthrough in complementary cancer care, offering hope for patients seeking additional support during challenging treatment protocols. The scientific validation provided by the NCI Drug Dictionary listing underscores the growing importance of researching and developing advanced herbal supplements with targeted therapeutic potential.
Curated from 24-7 Press Release
